Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial

BACKGROUND: NVA237 is a once-daily dry-powder formulation of the long-acting muscarinic antagonist glycopyrronium bromide in development for the treatment of chronic obstructive pulmonary disease (COPD). The glycopyrronium bromide in COPD airways clinical study 1 (GLOW1) evaluated the efficacy, safe...

Descripción completa

Detalles Bibliográficos
Autores principales: D'Urzo, Anthony, Ferguson, Gary T, van Noord, Jan A, Hirata, Kazuto, Martin, Carmen, Horton, Rachael, Lu, Yimeng, Banerji, Donald, Overend, Tim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3266210/
https://www.ncbi.nlm.nih.gov/pubmed/22151296
http://dx.doi.org/10.1186/1465-9921-12-156

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3266210/
https://www.ncbi.nlm.nih.gov/pubmed/22151296
http://dx.doi.org/10.1186/1465-9921-12-156

Ejemplares similares